Can a second round of pertuzumab help fight advanced breast cancer?
NCT ID NCT02514681
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tested whether giving pertuzumab again, along with trastuzumab and chemotherapy, could help people with HER2-positive advanced breast cancer who had already received pertuzumab before. The study enrolled 226 participants and compared retreatment to standard trastuzumab and chemotherapy alone. The main goal was to see if retreatment could delay cancer progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pertuzumab (Perjeta) combined with trastuzumab (Herceptin) and chemotherapy drugs
- What this could lead to
- If successful, this could offer a new treatment option for people with HER2-positive advanced breast cancer who have already been treated with pertuzumab, potentially delaying disease progression.
- What could go wrong
- This is a completed phase 3 trial, but retreatment may not provide significant benefit over standard therapy. Side effects from chemotherapy and targeted drugs remain a risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aichi Cancer Center
Chikusa-ku, Aichi-ken, 4648681, Japan
-
Japan Breast Cancer Research Group
Chuo-ku, Nihonbashi, Koami-cho, Tokyo, 1030016, Japan
-
Kumamoto University Hospital
Kumamoto, Kumamoto, 8608556, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.